Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ:IRWD)

3.655 +0.005 (+0.14%)

Delayed Quote Updated: 11:49 AM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ironwood Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.

November 04, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021

October 25, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host Third Quarter 2021 Investor Update Call

October 21, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Stocks That Hit 52-Week Highs On Thursday ↗

July 29, 2021

Thursday's morning session saw 167 companies set new 52-week highs. Points of Interest: ASML Holding (NASDAQ:ASML) was the largest company by market cap to set a new...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

3 Cheap Healthcare Stocks to Buy Right Now ↗

September 24, 2021

The COVID-19 pandemic brought a renewed interest into the healthcare sector, and with the surging Delta variant raging across the country, that interest isn’t expected to dissipate anytime soon.

Via Talk Markets

Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences

September 02, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label

August 26, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals, inc (IRWD) Q2 2021 Earnings Call Transcript ↗

August 05, 2021

IRWD earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO ↗

August 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (...

Via Benzinga

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗

August 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...

Via Benzinga

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering ↗

August 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,...

Via Benzinga

Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance

August 05, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer

August 03, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host Second Quarter 2021 Investor Update Call

July 22, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs ↗

July 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

June 16, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs ↗

July 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO ↗

June 24, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ...

Via Benzinga

The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex ↗

June 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc...

Via Benzinga

Ironwood Pharmaceuticals Announces Leadership Updates

June 07, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

3 Cheap Pharmaceutical Stocks to Grab Now ↗

May 28, 2021

The pharmaceutical industry has been the beneficiary of significant investor attention amid the COVID-19 pandemic as society turned to its products to fight the coronavirus.

Via Talk Markets

Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS® (linaclotide) 72 mcg Dosage Strength

May 26, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs ↗

May 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)...

Via Benzinga

More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (DDW)

May 24, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Disease Week® 2021

May 17, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Inc (IRWD) Q1 2021 Earnings Call Transcript ↗

May 06, 2021

IRWD earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Recap: Ironwood Pharmaceuticals Q1 Earnings ↗

May 06, 2021

Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were up 500.00% over the...

Via Benzinga

Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program

May 06, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗

May 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.